35
347
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T11777 | KRas G12C inhibitor 2 | Ras | GPCR/G Protein; MAPK |
KRas G12C inhibitor 2 is a compound that inhibits KRas G12C. | |||
T8369 |
Adagrasib
MRTX849 |
Ras | GPCR/G Protein; MAPK |
Adagrasib (MRTX849) 是一种 KRAS G12C 共价抑制剂,具有口服活性和选择性。Adagrasib 与 KRAS G12C 非活性构象的 GDP 状态结合,抑制 KRAS 及其下游信号的传导。Adagrasib 对 KRAS G12C 突变肿瘤具有抑制活性。 | |||
T9533 |
BC-LI-0186
4-(2,3-dimethyl-5-oxo-4-propan-2-ylpyrazol-1-yl)-N-(2-phenoxyethyl)benzenesulfonamide |
Others | Others |
BC-LI-0186 (4-(2,3-dimethyl-5-oxo-4-propan-2-ylpyrazol-1-yl)-N-(2-phenoxyethyl)benzenesulfonamide) 是选择性抑制亮氨酸 tRNA 合成酶与 Ras 相关的 GTP 结合蛋白 D 相互作用(IC50=46.11 nM)。BC-LI-0186能有效抑制肿瘤相关 MTOR 突变体的特性和雷帕霉素耐药癌细胞的生长,能够用于肺癌的相关研究。 | |||
T79800 |
pan-KRAS-IN-2
|
Ras | GPCR/G Protein; MAPK |
Pan-KRAS-IN-2(compound 6)是一种抑制剂,对KRAS WT及其多种突变体(G12D、G12C、G12V、G12S、G12A、Q61H)表现出极高的抑制活性,其IC50均不超过10 nM;然而对KRAS G13D的抑制活性较低,IC50超过10 μM。 | |||
T18055 |
K-Ras ligand-Linker Conjugate 2
|
Others | Others |
K-Ras ligand-Linker Conjugate 2 is a chemical compound that includes a ligand for K-Ras and a PROTAC linker. This compound is capable of recruiting E3 ligases like VHL, CRBN, MDM2, and IAP. It is utilized in the synthesis of PROTAC K-Ras Degrader-1, which is a highly effective PROTAC K-Ras degrader with a degradation efficacy of ≥70% in SW1573 cells[1]. | |||
T11736 |
K-Ras G12C-IN-2
|
Others | Others |
K-Ras G12C-IN-2 is a covalent kras g12c inhibitor. | |||
T36256 |
LC-2
LC 2,PROTAC KRASG12C Degrader-LC-2,LC2 |
PROTACs | PROTAC |
LC-2 (PROTAC KRASG12C Degrader-LC-2) 是一种新型基于von Hippel-Lindau的内源性 KRAS G12C 的 PROTAC 降解剂,DC50 在 0.25 和 0.76 μM 之间。LC-2 是一种与 MRTX849 共价结合 KRAS G12C 并招募 E3 连接酶 VH的 PROTAC,诱导 KRAS G12C 快速持续降解。LC-2 对纯合和杂合子 KRAS G12C 细胞系 MAPK 信号有抑制作用。 | |||
T11224 |
Rineterkib
ERK-IN-1 |
ERK; Raf | MAPK |
Rineterkib (ERK-IN-1) 是口服有效的RAF 和ERK1/2的抑制剂,与 KRAS-突变型非小细胞肺癌、BRAF-突变型非小细胞肺癌、KRAS-突变型胰腺癌、KRAS -突变型结肠癌和 KRAS-突变型卵巢癌尤为相关。 | |||
T9585 |
GNE-9815
3-(2-cyanopropan-2-yl)-N-[2-fluoro-4-methyl-5-(7-methyl-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-3-yl)phenyl]benzamide |
Raf | MAPK |
GNE-9815 (3-(2-cyanopropan-2-yl)-N-[2-fluoro-4-methyl-5-(7-methyl-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-3-yl)phenyl]benzamide) 是一种高激酶选择性 RAF 抑制剂,可用于通过联合治疗靶向 KRAS 突变癌症。 | |||
T74698 |
RMC-6236
RAS-IN-2 |
||
RMC-6236是一种相关的 RAS(ON) 多选择性抑制剂,对CypA蛋白(KD1)的亲和力为55.3 nmol/L,RMC-6236对KRAS突变癌细胞系HPAC (KRASG12D/WT, PDAC)和Capan-2 (KRASG12V/WT, PDAC), EC50分别为1.2和1.4 nmol/L,可用于癌症治疗。[1,2] | |||
T7123 |
AMG-47a
|
VEGFR; p38 MAPK; JAK; Src | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; MAPK; Stem Cells; Tyrosine Kinase/Adaptors |
AMG-47a 是具有口服活性的 Lck 抑制剂,IC50值为 0.2 nM。它具有抗炎作用,对 VEGF2、p38α、p38α、Jak3、MLR 和 IL-2的 IC50值分别为 1、3、72、30 和 21 nM。 | |||
T60202 |
MMRi62
7-[(2,3-dichlorophenyl)-(pyridin-2-ylamino)methyl]quinolin-8-ol |
Ferroptosis | Apoptosis |
MMRi62 (7-[(2,3-dichlorophenyl)-(pyridin-2-ylamino)methyl]quinolin-8-ol) 是一种铁死亡 (ferroptosis) 诱导剂,靶向 MDM2-MDM4 (抑癌基因 p53 负调控因子)。MMRi62 对胰腺导管腺癌 (PDAC) 细胞显示出 p53 独立的促凋亡 (apoptosis) 活性,并诱导其自噬 (autophagy)。MMRi62 诱导铁死亡,伴随着活性氧增加和铁蛋白重链 (FTH1) 溶酶体降解。MMRi62 还可导致突变型 p53 的蛋白酶体降解,并对具有 KRAS 和 TP53 高频突变特征的原位异种移植 PDAC 小鼠模型具有体内药效。 | |||
T79162 | SOS1/KRAS-IN-1 | Ras | GPCR/G Protein; MAPK |
SOS1/KRAS-IN-1(Compound 2)为针对SOS1/KRAS介导的疾病进行研究而设计的抑制剂。 | |||
T37130 | MRTX1133 formic | ||
MRTX1133 is a highly selective, first-in-class inhibitor of KRAS G12D. MRTX1133 targets the KRAS G12D protein in both active and inactive states. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells[1][2]. MRTX1133 demonstrates dose-dependent inhibition of the KRAS pathway tumor regression in G12D mutant tumor models[2]. [1]. Xiaolun Wang, et al.Kras g12d inhibitors.WO2021041671A1.[2]. KRAS G12D Inhibitor: MRTX1133. [(accessed on 22 April 2021)];2021 Available onli... | |||
T62737 |
KRAS inhibitor-15
|
||
KRAS inhibitor-15 (compound 3-19) 是一种 KRAS G12C 的有效抑制剂 (IC50: 0.954 μM)。KRAS inhibitor-15 在 MIA PaCA-2,A549 细胞中表现出 p-ERK 抑制作用,IC50s 分别为 2.03,>33.3 μM。KRAS inhibitor-15 具有潜力进行胰腺癌、结直肠癌和肺癌的研究。 | |||
T63164 | KRAS inhibitor-13 | ||
KRAS inhibitor-13 (compound 5-6) 是一种 KRAS G12C 的有效抑制剂 (IC50: 0.883 μM)。KRAS inhibitor-13 在 MIA PaCA-2,A549 细胞中具有 p-ERK 抑制效果,其 IC50 值分别为 5.9,>100 μM。 KRAS inhibitor-13 具有潜力进行胰腺癌、结直肠癌和肺癌的研究。 | |||
T63863 |
KRAS G12C inhibitor 47
|
||
KRAS G12C inhibitor 47 是 KRAS G12C 的有效抑制剂 (IC50: 0.172 μM)。KRAS G12C inhibitor 47 在 MIA PaCA-2 细胞、A549 细胞中表现出 p-ERK 抑制作用,他们的 IC50 值分别为 0.046 μM、69.8 μM。KRAS G12C inhibitor 47 对胰腺癌,结直肠癌和肺癌表现出研究潜力。 | |||
T63235 |
KRAS inhibitor-14
|
||
KRAS inhibitor-14 是 KRAS G12C 的有效抑制剂(IC50: 0.249 μM)。KRAS inhibitor-14 在 MIA PaCA-2,A549 细胞中表现出 p-ERK 抑制作用,IC50s 分别为 1.12,>33.3 μM。KRAS inhibitor-14 对胰腺癌、结直肠癌和肺癌的具有研究潜力。 | |||
T36676 |
Rineterkib hydrochloride
|
||
Rineterkib hydrochloride (compound B) is an orally active RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer[1]. ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the C... | |||
T64093 | KRAS G12C inhibitor 44 | ||
KRAS G12C inhibitor 44 是一种有效的、口服具有活力的 KRAS G12C 抑制剂。KRAS G12C inhibitor 44 在 MIA PaCA-2 (IC50: 0.016 μM)、H358 细胞 (IC50: 0.028 μM) 中表现出抗增殖作用。KRAS G12C inhibitor 44 在体内具有抗肿瘤活性。 | |||
T62752 | KRAS inhibitor-16 | ||
KRAS inhibitor-16 (compound 3-11) 是一种 KRAS G12C 的有效抑制剂 (IC50: 0.457 μM)。KRAS inhibitor-16 在 MIA PaCA-2,A549 细胞中表现出 p-ERK 抑制作用,IC50s 分别为 3.06,11.1 μM。 KRAS inhibitor-16 具有潜力进行胰腺癌,结直肠癌和肺癌的研究。 | |||
T62784 |
KRAS inhibitor-18
|
||
KRAS inhibitor-18 (compound 3-10) 是一种 KRAS G12C 的有效抑制剂 (IC50: 4.74 μM)。KRAS inhibitor-18 在 MIA PaCA-2,A549 细胞中表现出 p-ERK 抑制作用,IC50s 分别为 66.4,11.1 μM。KRAS inhibitor-18 具有潜力进行胰腺癌、结直肠癌和肺癌的研究。 | |||
T62981 | KRAS inhibitor-17 | ||
KRAS inhibitor-17 (compound 3-9) 是一种 KRAS G12C 的有效抑制剂 (IC50: 3.37 μM)。KRAS inhibitor-17 具有 p-ERK 抑制作用,在 MIA PaCA-2 细胞的 IC50=9.25 μM,在 A549 细胞中的 IC50 >33.3 μM。KRAS inhibitor-17 具有潜力进行胰腺癌,结直肠癌和肺癌的研究。 | |||
T62751 | KRAS inhibitor-12 | ||
KRAS inhibitor-12 (compound 6-1) 是一种 KRAS G12C 的有效抑制剂 (IC50: 0.537 μM)。KRAS inhibitor-12 在 MIA PaCA-2,A549 细胞中表现出 p-ERK 抑制作用,其 IC50 值分别为 1.3,3.7 μM。 KRAS inhibitor-12 具有潜力进行胰腺癌,结直肠癌和肺癌的研究。 | |||
T79673 |
LUNA18
|
Ras | GPCR/G Protein; MAPK |
LUNA18作为口服活性KRAS抑制剂,其对KRASG12D-SOS的IC50值<2 nM,适用于癌症研究。 | |||
T40190 |
MRTX849 ethoxypropanoic acid
|
||
MRTX849 ethoxypropanoic acid is a compound that contains a ligand for KRAS G12C and a PROTAC linker. It is commonly employed in the synthesis of PROTAC LC-2, which is a highly effective and innovative PROTAC. LC-2 has been proven to degrade endogenous KRAS G12C with remarkable potency, exhibiting DC50 values ranging from 0.25 to 0.76 μM. | |||
T79808 |
KRAS G12C inhibitor 61
|
ERK | MAPK |
KRAS G12C inhibitor 61 (Example 3) 在 MIA PaCa-2 细胞中抑制 ERK1/2 磷酸化,其 IC50 为 9 nM。此化合物适用于胰腺癌、结直肠癌和肺癌的研究。 | |||
T12934 |
SMAP-2
DT-1154 |
Phosphatase | Metabolism |
SMAP-2 is an orally bioavailable activator of phosphatase 2A (PP2A) which binds to the PP2A Aα scaffold subunit to drive conformational changes in PP2A. It inhibits the growth of KRAS-mutant lung cancers . | |||
T72971 |
(S)-JDQ-443
(S)-NVP-JDQ443 |
||
(S)-JDQ-443 是 JDQ-443的异构体。JDQ-443 是一种口服有效和选择性的共价 KRAS G12C 抑制剂。JDQ-443 具有抗肿瘤活性。 | |||
T40189 |
MRTX849 acid
MRTX849 acid |
||
MRTX849 acid, a derivative of MRTX849, is employed in the synthesis of PROTAC LC-2. LC-2, a potent and pioneering PROTAC, exhibits the ability to efficiently degrade endogenous KRAS G12C with DC50 values ranging between 0.25 and 0.76 μM. | |||
T75119 | KRASG12C IN-2 | ||
KRASG12C IN-2 (化合物 17) 是一种口服有效的KRASG12C 抑制剂。KRASG12C IN-2 能有效抑制小鼠体内肿瘤生长。 | |||
T78896 |
SHP2-IN-22
|
||
SHP2-IN-22 作为变构抑制剂,靶向SHP2,具有 17.7 nM 的 IC50。该化合物能够有效抑制MIA PaCa-2胰腺癌细胞的增殖、迁移和侵袭行为。SHP2-IN-22 主要用于研究含Kirsten大鼠肉瘤病毒癌基因(KRAS)突变型的癌症。 | |||
T74920 | G12Si-2 | ||
G12Si-2,一种 G12Si-1 的类似物,可作为阴性对照。G12Si-2 不是 KRAS G12S 突变体的共价抑制剂。 | |||
T23337 |
SCH772984 HCl
|
ERK; Others | MAPK; Others |
SCH772984 HCl 是一种特异性的 ERK1/2 抑制剂,具有 I 型和 II 型激酶抑制剂的特性,其 IC50 分别为 4 和 1 nM。 SCH772984 HCl 在 BRAF、NRAS 或 KRAS 突变的肿瘤细胞中具有纳摩尔级细胞效力,并诱导肿瘤消退。 SCH772984 HCl 可用于 MAPK 抑制剂难治性肿瘤的研究。 | |||
T36779 |
NG 25 (hydrochloride hydrate)
|
||
NG 25 is a type II kinase inhibitor that inhibits MAP4K2 and TAK1 (IC50s = 21.7 and 149 nM, respectively).1It also inhibits the Src family kinases Src and LYN (IC50s = 113 and 12.9 nM, respectively) and Abl family kinases (IC50s = 75.2 nM), as well as CSK, FER, and p38α (IC50s = 56.4, 82.3, and 102 nM, respectively). NG 25 (100 nM) prevents TNF-α-induced IKKα/β phosphorylation and IκB-α degradation in L929 cells. It inhibits secretion of IFN-α and IFN-β induced by CpG type B and CL097, respectiv... |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04116 |
KRAS Protein,Human,Recombinant(G12C & Q61H, His)
NS,CFC2,K-RAS4B,C-K-RAS,KRAS2,K-R... |
Human | E. coli |
KRAS Protein,Human,Recombinant(G12C & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2. | |||
TMPY-06056 |
KRAS Protein, Human, Recombinant (G12D, His)
KRAS1,K-RAS4B,Kirsten rat sarcoma viral oncogene ho... |
Human | E. coli |
KRAS Protein, Human, Recombinant (G12D, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 22 kDa and the accession number is P01116-2. | |||
TMPY-01888 |
KRAS Protein,Human, Recombinant (Q61H, His)
KRAS2,C-K-RAS,Kirsten rat sarcoma viral on... |
Human | E. coli |
KRAS Protein,Human, Recombinant (Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 22.5 kDa and the accession number is P01116-2. | |||
TMPY-04113 |
KRAS Protein,Human,Recombinant(G12D & Q61H, His)
Kirsten rat sarcoma viral oncogene homolog,KRAS... |
Human | E. coli |
KRAS Protein,Human,Recombinant(G12D & Q61H, His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 23.3 kDa and the accession number is P01116-2. | |||
TMPK-01399 |
HLA-A*11:01&B2M&KRAS WT (VVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
K-RAS2A,NS3,KRAS2,CFC2,K... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01479 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
NS3,KRAS1,K-Ras 2,K-RAS2A,K-RAS |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01488 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,MHC,GTPase Kras,K-Ras 2,KRAS |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01510 |
HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)
NS,NS3,KRAS2,RASK2,MHC,RALD,K-Ras... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01511 |
HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
GTPase Kras,K-RAS4A,KI-RAS,K-RAS4B,C-K-RAS,K-Ras |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01512 |
HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)
K-Ras 2,NS,NS3,K-RAS2B,CFC2,MHC,<... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01461 |
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi)
C-K-RAS,KRAS,RASK2,K-Ras 2,K-RAS<... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01434 |
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Tetramer Protein, Human, MHC (His & Avi)
RASK2,CFC2,GTPase Kras,KRAS |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01458 |
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)
K-Ras 2,GTPase Kras,KRAS2 |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01427 |
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
C-K-RAS,K-RAS4B,GTPase Kras,K-RAS4A,K-RAS2... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01525 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CFC2,RALD,K-Ras 2,MHC,C-K-RAS,NS3,GTPase <... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01489 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)
K-RAS2A,NS3,KRAS1,KRAS2,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01529 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,KRAS1,MHC,K-RAS2B,CFC2,GT... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01463 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)
C-K-RAS,KI-RAS,KRAS1,K-RAS4A,KRAS2 |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01518 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)
MHC,NS,KRAS1,K-RAS2A,GTPase Kras,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01527 |
HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)
NS,RALD,C-K-RAS,RASK2,K-RAS2B,KRAS |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01433 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)
GTPase Kras,NS3,K-Ras 2,K-RAS2B,R... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01401 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
MHC,CFC2,K-Ras 2,RALD,K-RAS4A,NS,RASK2... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01428 |
HLA-A*11:01&B2M&KRAS G12D (VVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
CFC2,K-RAS4B,K-Ras 2,C-K-RAS,RASK2 |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01432 |
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein, Human, MHC (His & Avi)
RASK2,K-RAS4A,K-RAS4B,KRAS2,CFC |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01408 |
HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
RALD,KRAS1,KRAS2,K-RAS2B... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2 |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01407 |
HLA-A*02:01&B2M&KRAS WT (KLVVVGAGGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS2,RALD,C-K-RAS,NS3,MHC,CFC2,<... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01462 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
K-RAS4A,K-RAS2A,CFC2,KRAS1,K-RAS4... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01460 |
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,K-RAS2A,KI-RAS,K-RAS4B,RALD,NS3,GTPase Kras... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01403 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
K-Ras 2,KI-RAS,CFC2,KRAS1,GTPase ... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01528 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)
KRAS1,MHC,K-RAS2B,K-RAS4B,NS,GTPase Kr... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01465 |
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS2A,CFC2,KRAS,GTPase ... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01507 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer Protein, Human, MHC (His & Avi)
K-RAS2A,K-RAS4B,KI-RAS,RALD,C-K-RAS,RASK2,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01438 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
RASK2,KRAS2,KRAS1,MHC,C-... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01404 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
NS,KRAS,KRAS1,KRAS2,MHC,... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS<... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01405 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
KI-RAS,RASK2,K-Ras 2,MHC,KRAS, |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01443 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled
KRAS1,C-K-RAS,K-RAS4B,RALD,K-Ras 2,K-RAS |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01526 |
HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)
KRAS,NS3,GTPase Kras,RASK2,K-RAS<... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01457 |
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
K-Ras 2,CFC2,RALD,MHC,KRAS,K-RAS4... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01490 |
HLA-A*11:01&B2M&KRAS G12V (VVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS2A,GTPase Kras,K-Ras 2,RALD,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01431 |
HLA-A*11:01&B2M&KRAS G12S (VVVGASGVGK) Tetramer Protein, Human, MHC (His & Avi)
RALD,C-K-RAS,MHC,K-RAS2A,GTPase Kras,K... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01471 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi), FITC-Labeled
CFC2,KRAS,K-RAS4B,MHC,K-RAS2B, |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01429 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
MHC,K-Ras 2,NS,K-RAS4A,KRAS,NS3,KI-RAS,K-R... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01536 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
NS3,MHC,KRAS,RALD,CFC2,K-RAS2B,GT... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01464 |
HLA-A*11:01&B2M&KRAS G12R (VVVGARGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
C-K-RAS,K-RAS4A,GTPase Kras,K-RAS2A,NS,K-R... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01453 |
HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
RASK2,CFC2,K-Ras 2,NS3,GTPase |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01537 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi), Biotinylated
K-RAS4A,NS,C-K-RAS,RALD,GTPase Kras,K-RAS2... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01400 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
NS,KRAS1,RALD,K-RAS2A,K-RAS2B,K-R... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
------------------------ 更多 ------------------------ |